Marrone Bio Innovations, Inc.
MBII
MBII was delisted on the 12th of July, 2022.
0 hedge funds and large institutions have $0 invested in Marrone Bio Innovations, Inc. in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 62 closing their positions.
100% less funds holding
Funds holding: 62 → 0 (-62)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $45M → $0 (-$45M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 62
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$21.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.64M |
| 3 |
SC
Shay Capital
New York
|
-$2.49M |
| 4 |
GLAM
Gardner Lewis Asset Management
Chadds Ford,
Pennsylvania
|
-$2.32M |
| 5 |
Primecap Management
Pasadena,
California
|
-$1.69M |
MBII Hedge Fund Activity: Q3 2022 in Review
0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Marrone Bio Innovations, Inc. (MBII) for Q3 2022, worth a combined $0 — down 100% from $45M a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of MBII and 0 opened new positions — a net loss of 62 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $21.3M sold.
- 0 institutional investors held Marrone Bio Innovations, Inc. (MBII) as of Q3 2022, down from 62 in Q2 2022.
- Funds reported $0 of Marrone Bio Innovations, Inc. stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new Marrone Bio Innovations, Inc. positions in Q3 2022 and 62 closed out, a net change of -62 holders.
- The largest Marrone Bio Innovations, Inc. seller in Q3 2022 was Ardsley Advisory Partners, an estimated $21.3M sold.
Based on aggregated 13F filings for Q3 2022.